Ceftazidime: Difference between revisions
(Replaced content with "{{Ceftazidime}} __NOTOC__ {{CMG}}") |
No edit summary |
||
| Line 2: | Line 2: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | {{CMG}} | ||
==Overview== | |||
'''Ceftazidime''' ([[International Nonproprietary Name|INN]]) ([[International Phonetic Alphabet|IPA]]: {{IPA|[kɛfˈtæzədim, sɛf-]}}) is a third-generation[[cephalosporin]] [[antibiotic]]. Like other third-generation cephalosporins, it has broad spectrum activity against [[Gram-positive]] and [[Gram-negative]][[bacteria]]. Unlike most third-generation agents, it is active against ''[[Pseudomonas aeruginosa]]'', however it has weaker activity against Gram-positive microorganisms and is not used for such infections. | |||
==Category== | |||
Cephalosporin, Third-Generation | |||
==US Brand Names== | |||
FORATZ<sup>®</sup>,TAZICEF<sup>®</sup>,CEFTAZIDIME<sup>®</sup>. | |||
==Mechanism of action== | |||
==FDA Package Insert== | |||
'''[[Ceftazidime description|Description]]''' | |||
'''| [[Ceftazidime clinical pharmacology|Clinical Pharmacology]]''' | |||
'''| [[Ceftazidime microbiology|Microbiology]]''' | |||
'''| [[Ceftazidime indications and usage|Indications and Usage]]''' | |||
'''| [[Ceftazidime contraindications|Contraindications]]''' | |||
'''| [[Ceftazidime warnings|Warnings]]''' | |||
'''| [[Ceftazidime precautions|Precautions]]''' | |||
'''| [[Ceftazidime adverse reactions|Adverse Reactions]]''' | |||
'''| [[Ceftazidime overdosage|Overdosage]]''' | |||
'''| [[Ceftazidime clinical studies|Clinical Studies]]''' | |||
'''| [[Ceftazidime dosage and administration|Dosage and Administration]]''' | |||
'''| [[Ceftazidime compatibility reconstitution and stability|Compatibility, Reconstitution, and Stability]]''' | |||
'''| [[Ceftazidime directions for use|Directions For Use]]''' | |||
'''| [[Ceftazidime how supplied|How Supplied]]''' | |||
'''| [[Ceftazidime labels and packages|Labels and Packages]]''' | |||
Revision as of 19:52, 26 December 2013
| Ceftazidime |
|---|
| FORATZ®,TAZICEF®,CEFTAZIDIME® FDA Package Insert |
| Description |
| Clinical Pharmacology |
| Microbiology |
| Indications and Usage |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Overdosage |
| Dosage and Administration |
| Compatibility and stability |
| Directions for use |
| How Supplied |
| Labels and Packages |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Ceftazidime (INN) (IPA: Template:IPA) is a third-generationcephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram-positive and Gram-negativebacteria. Unlike most third-generation agents, it is active against Pseudomonas aeruginosa, however it has weaker activity against Gram-positive microorganisms and is not used for such infections.
Category
Cephalosporin, Third-Generation
US Brand Names
FORATZ®,TAZICEF®,CEFTAZIDIME®.
Mechanism of action
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages